MARKET NEWS

Mereo BioPharma & Oncologie Enter Global Licensing Agreement
OncoCyte Announces Agreement to Acquire Molecular Diagnostics Company
Innovative Micro-Infusion Pump From Gerresheimer Subsidiary Sensile Medical for EVER Pharma
CytoDyn Files for Breakthrough Therapy Designation With the FDA
Adaptimmune Announces SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications
Novavax Granted Fast-Track Designation

  FEATURED EDITORIAL

  COMPANY PROFILE

 

Adare Pharmaceuticals is a global specialty CDMO providing product development through commercial manufacturing expertise focused on oral dosage forms for the Pharmaceutical, Animal Health and OTC markets.  Adare’s proprietary technology platforms specialize in ODT, taste masking and customized drug release. With over 30 years of proven legacy, Adare has successfully developed and manufactured more than 40 products sold by partners in more than 100 countries globally. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Interpace Biosciences Enters Agreement for -Million Investment 

Interpace Biosciences Enters Agreement for $20-Million Investment 

Interpace Biosciences, Inc. recently announced that it has entered into an agreement for a new Series B Preferred Stock investment of….

Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimer’s Disease and Parkinson’s Disease

Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimer’s Disease and Parkinson’s Disease

Biogen Inc. recently announced an agreement to acquire from Pfizer Inc. a novel CNS-penetrant small molecule inhibitor of casein kinase 1 (CK1), for the potential treatment of patients with…

Codexis & Nestlé Health Science Sign Development Agreement

Codexis & Nestlé Health Science Sign Development Agreement

Codexis, Inc. and Nestlé Health Science have signed an agreement to advance a lead candidate discovered through a Strategic Collaboration Agreement (SCA) into preclinical….

Adare Pharmaceuticals & NLS Pharmaceutics Collaborate to Develop Controlled-Release Candidates

Adare Pharmaceuticals & NLS Pharmaceutics Collaborate to Develop Controlled-Release Candidates

Adare Pharmaceuticals, Inc. and NLS Pharmaceutics Ltd. recently announced a collaboration to develop mazindol (MZD) CR product candidates for the treatment of….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

January 29 – Bioavailability
February 5 – Analytical Testing